ReviewBioengineered bugs
The Bacterial Ghost platform system: production and applications.
Review in Bioengineered bugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 193 citations in OpenAlex.
- Escherichia coli DH5α-loaded fenugreek extract: an effective anticancer combination against human breast cancer cell lines.Applied microbiology and biotechnology · 2026Article
- Functional Activity of the Lysis Protein E From Phage ID52: Dependence on SecB for Efficient Host Cell Lysis.Biotechnology journal · 2026Article
- Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs.ChemMedChem · 2026Article
- Bacterial ghosts (BGs): A promising approach as candidate vaccine.World journal of microbiology & biotechnology · 2026Review
- A Chemically InducedVaccines · 2026Article
- Engineered nano-bacteria hybrids for precision cancer immunotherapy.Materials today. Bio · 2025Review
- Oral Vaccination withVaccines · 2025Article
- Analysis of the efficacy of two molecular adjuvants, flagellin and IFN-γ, on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus).Fish physiology and biochemistry · 2025Article
- Article
- Development of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy.Acta pharmaceutica Sinica. B · 2024Article
- NovelHeliyon · 2024Article
- Bactofection, Bacterial-Mediated Vaccination, and Cancer Therapy: Current Applications and Future Perspectives.Vaccines · 2024Review
- Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy.Journal of nanobiotechnology · 2024Review
- Bacteriophage-encoded protein utilization in bacterial ghost production: a mini-review.World journal of microbiology & biotechnology · 2024Review
- Deciphering the Potential of Probiotics in Vaccines.Vaccines · 2024Review
- Bacterial extracellular vesicles: biotechnological perspective for enhanced productivity.World journal of microbiology & biotechnology · 2024Review
- Delivery of a Hepatitis C Virus Vaccine Encoding NS3 Linked to the MHC Class II Chaperone Protein Invariant Chain Using Bacterial Ghosts.Biomedicines · 2024Article
- Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024Review
- Comparison of the immune effects of theFrontiers in microbiology · 2024Article
- Advances in bacteria-based drug delivery systems for anti-tumor therapy.Clinical & translational immunology · 2024Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Bacterial Ghost (BG) platform technology is an innovative system for vaccine, drug or active substance delivery and for technical applications in white biotechnology. BGs are cell envelopes derived from Gram-negative bacteria. BGs are devoid of all cytoplasmic content but have a preserved cellular morphology including all cell surface structures. Using BGs as delivery vehicles for subunit or DNA-vaccines the particle structure and surface properties of BGs are targeting the carrier itself to primary antigen-presenting cells. Furthermore, BGs exhibit intrinsic adjuvant properties and trigger an enhanced humoral and cellular immune response to the target antigen. Multiple antigens of the native BG envelope and recombinant protein or DNA antigens can be combined in a single type of BG. Antigens can be presented on the inner or outer membrane of the BG as well as in the periplasm that is sealed during BG formation. Drugs or supplements can also be loaded to the internal lumen or periplasmic space of the carrier. BGs are produced by batch fermentation with subsequent product recovery and purification via tangential flow filtration. For safety reasons all residual bacterial DNA is inactivated during the BG production process by the use of staphylococcal nuclease A and/or the treatment with β-propiolactone. After purification BGs can be stored long-term at ambient room temperature as lyophilized product. The production cycle from the inoculation of the pre-culture to the purified BG concentrate ready for lyophilization does not take longer than a day and thus meets modern criteria of rapid vaccine production rather than keeping large stocks of vaccines. The broad spectrum of possible applications in combination with the comparably low production costs make the BG platform technology a safe and sophisticated product for the targeted delivery of vaccines and active agents as well as carrier of immobilized enzymes for applications in white biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.